Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity. Chemotherapy drugs, such as docetaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Docetaxel and cyclophosphamide are commonly used, but is not well tolerated at the standard dose and can affect the way older patients feel physically and emotionally. Giving dose-red

Trial Details

NCT ID
NCT06042569
Phase
PHASE2
Sponsor
City of Hope Medical Center
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Cyclophosphamide
  • Docetaxel
  • Medical Chart Review
  • Questionnaire Administration
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Rochester, New York, United States|43.15478,-77.61556

Key Eligibility Criteria

  • Ability to provided informed consent or a legally authorized representative is able to consent on behalf of the patient
  • Willing to answer questionnaires as part of their participation
  • Age: \>= 65 years by the time of study registration
  • Histologically or cytologically confirmed breast cancer(s) that is human epidermal growth factor receptor 2 negative (HER2-negative) per the most r…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →